Antabio Overview

  • Founded
  • 2009
Founded
  • Status
  • Private
  • Employees
  • 19
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $6.38M
Latest Deal Amount
  • Investors
  • 10

Antabio General Information

Description

Developer of antibacterial resistance-breakers designed to treat drug-resistant infections in areas of unmet medical need. The company's resistance-breakers develops stand-alone inhibitors of bacterial metalloenzymes that can be combined with various antibiotics to restore their activity against the most critical pathogens, enabling health professionals to get access to medicinal products that help in curing drug-resistant diseases.

Contact Information

Website
www.antabio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 436, Rue Pierre et Marie Curie
  • 31670 Labège
  • France
+33 05 00 00 00 00

Antabio Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Antabio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Grant 16-Mar-2021 $6.38M 000.00 Completed Generating Revenue
7. Later Stage VC 00.000 000.00 Completed Generating Revenue
6. Later Stage VC (Series A) 12-Jul-2018 0000 000.00 000.00 Completed Generating Revenue
5. Grant 25-Jul-2017 00.00 00000 Completed Generating Revenue
4. Grant 01-Jan-2015 00.000 00000 Completed Generating Revenue
3. Accelerator/Incubator 00000 00000 Completed Generating Revenue
2. Grant 01-Jan-2013 $6.17M $400K Completed Generating Revenue
1. Equity Crowdfunding 10-Jan-2012 $400K $400K Completed Generating Revenue
To view Antabio’s complete valuation and funding history, request access »

Antabio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
A2 Preference 00,000 00.000000 0000.0 0000.0 0000.0 00.000
To view Antabio’s complete cap table history, request access »

Antabio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of antibacterial resistance-breakers designed to treat drug-resistant infections in areas of unmet medical nee
Drug Discovery
Labège, France
19 As of 2021
000.00
0000000000 000.00

00000000

tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitati
0000 000000000
Union, NJ
0000000000

00000 00

et, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
0000000000000
Cambridge, MA
00 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Antabio Competitors (7)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Prokaryotics Corporation Union, NJ 0000000000
00000 000000000000 Formerly VC-backed Cambridge, MA 00 00000 000000 - 000 00000
0000000 0000000000 Venture Capital-Backed Lörrach, Germany 0 0000 0000000000 0 0000
00000000 Formerly VC-backed Tübingen, Germany 000 00000 000000000 00000
0000000 0000000000 Formerly PE-Backed Cambridge, MA 000 00000 000000000
You’re viewing 5 of 7 competitors. Get the full list »

Antabio Executive Team (5)

Name Title Board Seat Contact Info
Marc Lemonnier Ph.D Co-Founder, Chief Executive Officer & Board Member
Gordon Waldron Chief Financial Officer & Chairman
Martin Everett Ph.D Chief Scientific Officer
Helmuth Van Es Ph.D Co-Founder & Board Member
You’re viewing 4 of 5 executive team members. Get the full list »

Antabio Board Members (15)

Name Representing Role Since
Adriano Ali Antabio Board Observer 000 0000
Benedikt Timmerman Ph.D Self Board Member 000 0000
Bervin Bouani Self Board Member 000 0000
Christophe Ricard Antabio Board Member 000 0000
Claire Poulard Omnes Capital Board Member 000 0000
You’re viewing 5 of 15 board members. Get the full list »

Antabio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Antabio Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Languedoc-Roussillon Region Government 000 0000 000000 0
BNP Paribas Développement PE/Buyout Minority 000 0000 000000 0
Galia Gestion PE/Buyout Minority 000 0000 000000 0
Institut Régional de Développement Industriel Venture Capital Minority 000 0000 000000 0
iXO Private Equity PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »